BTB01303 is a (glutamate release) inhibitor. Cancer cells release high levels of (glutamate), which disrupts normal bone turnover and may lead to cancer-induced bone pain. BTB01303 has the potential to improve cancer-induced bone pain[1].
Molecular Weight:
324.16
CAS Number:
[652129-89-0]
Formula:
C15H11Cl2NO3
Target:
mGluR
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted